In this case, a monoclonal dubbed "Campath-1" was developed to bind CD52 using a mouse system.
It is a monoclonal antibody that targets CD52, a protein that is expressed on the surface of mature lymphocytes.
Bone marrow tumour cells express the following antigen targets CD20 (98.3%), CD22 (88.3%), CD40 (83.3%), CD52 (77.4%), IgM (83.3%), MUC1 core protein (57.8%), and 1D10 (50%).
CD52 |
To circumvent this problem, Greg Winter and his colleagues humanised Campath-1, by extracting the hypervariable loops that had specificity for CD52 and grafting them onto a human antibody framework.